BioMarin halts studies for Voxzogo in Noonan syndrome
Shares of BioMarin Pharmaceutical NASDAQ:BMRN slipped in premarket trading on Tuesday after the company announced plans to discontinue the development of its dwarfism therapy Voxzogo for Noonan syndrome, a rare genetically driven developmental disorder.According to a federal register on clinical st…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.